Home > Insider Trading > Filing (0001104659-13-029502)

Filing Details

Accession Number:: 0001104659-13-029502
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2013-04-15 20:10:26
Reporting Period:: 2013-03-07

Filing Date:: 2013-04-15
Accepted Time:: 2013-04-15 20:10:26
Original Submission Date:: 2013-03-11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1396814	Pacira Pharmaceuticals Inc.	PCRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1267959	A Fred Middleton	C/O Sanderling Ventures 400 South El Camino Real, Suite 1200 San Mateo CA 94402	Yes	No	Yes	No
1306695	Sanderling Venture Partners Vi Co Investment Fund Lp	C/O Sanderling Ventures 400 South El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No
1306717	Sanderling Venture Partners Vi Lp	C/O Sanderling Ventures 400 South El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No
1429282	Partnership Limited Vi Sanderling	C/O Sanderling Ventures 400 South El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No
1429283	Sanderling Vi Beteiligungs Gmbh & Co Kg	C/O Sanderling Ventures 400 South El Camino Real, Suite 1200 San Mateo CA 94402	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-03-07	17,973	$2.69	900,535	No	4	X	Direct
Common Stock	Acquisiton	2013-03-07	629	$2.69	48,383	No	4	X	Direct
Common Stock	Acquisiton	2013-03-07	750	$2.69	57,646	No	4	X	Direct
Common Stock	Acquisiton	2013-03-07	17,839	$2.69	1,353,952	No	4	X	Direct
Common Stock	Disposition	2013-03-07	1,866	$25.92	898,669	No	4	S	Direct
Common Stock	Disposition	2013-03-07	66	$25.92	48,317	No	4	S	Direct
Common Stock	Disposition	2013-03-07	78	$25.92	57,568	No	4	S	Direct
Common Stock	Disposition	2013-03-07	1,852	$25.92	1,352,100	No	4	S	Direct
Common Stock	Acquisiton	2013-03-07	20,220	$13.44	918,889	No	4	X	Direct
Common Stock	Acquisiton	2013-03-07	708	$13.44	49,025	No	4	X	Direct
Common Stock	Acquisiton	2013-03-07	843	$13.44	58,411	No	4	X	Direct
Common Stock	Acquisiton	2013-03-07	20,069	$13.44	1,372,169	No	4	X	Direct
Common Stock	Disposition	2013-03-07	10,485	$25.92	908,404	No	4	S	Direct
Common Stock	Disposition	2013-03-07	368	$25.92	48,657	No	4	S	Direct
Common Stock	Disposition	2013-03-07	438	$25.92	57,973	No	4	S	Direct
Common Stock	Disposition	2013-03-07	10,407	$25.92	1,361,762	No	4	S	Direct
Common Stock	Disposition	2013-03-11	348,951	$27.86	559,453	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	X	Direct
No	4	X	Direct
No	4	X	Direct
No	4	X	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	X	Direct
No	4	X	Direct
No	4	X	Direct
No	4	X	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock Warrants (right to buy)	Disposition	2013-03-07	17,973	$0.00	17,973	$2.69
Common Stock	Common Stock Warrants (right to buy)	Disposition	2013-03-07	629	$0.00	629	$2.69
Common Stock	Common Stock Warrants (right to buy)	Disposition	2013-03-07	750	$0.00	750	$2.69
Common Stock	Common Stock Warrants (right to buy)	Disposition	2013-03-07	17,839	$0.00	17,839	$2.69
Common Stock	Common Stock Warrants (right to buy)	Disposition	2013-03-07	20,220	$0.00	20,220	$13.44
Common Stock	Common Stock Warrants (right to buy)	Disposition	2013-03-07	708	$0.00	708	$13.44
Common Stock	Common Stock Warrants (right to buy)	Disposition	2013-03-07	843	$0.00	843	$13.44
Common Stock	Common Stock Warrants (right to buy)	Disposition	2013-03-07	20,069	$0.00	20,069	$13.44

Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2009-01-22	2014-01-21	No	4	X	Direct
2009-01-22	2014-01-21	No	4	X	Direct
2009-01-22	2014-01-21	No	4	X	Direct
2009-01-22	2014-01-21	No	4	X	Direct
2010-12-29	2017-12-29	No	4	X	Direct
2010-12-29	2017-12-29	No	4	X	Direct
2010-12-29	2017-12-29	No	4	X	Direct
2010-12-29	2017-12-29	No	4	X	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	42,833	Direct

Footnotes

The securities are held directly by Sanderling Venture Partners VI, L.P. The address for Sanderling Venture Partners VI , L.P. is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
The securities are held by Sanderling VI Beteiligungs GmbH & Co. KG. The address for Sanderling VI Beteiligungs GmbH & Co. KG is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
The securities are held directly by Sanderling VI Limited Partnership. The address for Sanderling VI Limited Partnership is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
The securities are held directly by Sanderling Venture Partners VI Co-Investment Fund, L.P. The address for Sanderling Venture Partners VI Co-Investment Fund, L.P. is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
Fred Middleton, a member of the Board of Directors of the Issuer, is a managing director of Middleton, McNeil, Mills & Associates VI, LLC, which has the ultimate voting and investment power over shares held of record by Sanderling Venture Partners VI, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling VI Limited Partnership and Sanderling Venture Partners VI Co-Investment Fund, L.P. and he may be deemed to have voting and investment power over shares held of record by Sanderling Venture Partners VI, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling VI Limited Partnership and Sanderling Venture Partners VI Co-Investment Fund, L.P.
On March 7, 2013, the reporting person exercised a warrant to purchase 17,973 shares of PCRX common stock for $2.69 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 1,866 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 16,107 shares. PCRX also paid $19.35 to the reporting person in lieu of a fractional share.
On March 7, 2013, the reporting person exercised a warrant to purchase 629 shares of PCRX common stock for $2.69 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 66 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 563 shares. PCRX also paid $18.71 to the reporting person in lieu of a fractional share.
On March 7, 2013, the reporting person exercised a warrant to purchase 750 shares of PCRX common stock for $2.69 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 78 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 672 shares. PCRX also paid $4.26 to the reporting person in lieu of a fractional share.
On March 7, 2013, the reporting person exercised a warrant to purchase 17,839 shares of PCRX common stock for $2.69 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 1,852 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 15,987 shares. PCRX also paid $16.93 to the reporting person in lieu of a fractional share.
On March 7, 2013, the reporting person exercised a warrant to purchase 20,220 shares of PCRX common stock for $13.44 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 10,485 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 9,735 shares. PCRX also paid $14.40 to the reporting person in lieu of a fractional share.
On March 7, 2013, the reporting person exercised a warrant to purchase 708 shares of PCRX common stock for $13.44 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 368 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 340 shares. PCRX also paid $23.04 to the reporting person in lieu of a fractional share.
On March 7, 2013, the reporting person exercised a warrant to purchase 843 shares of PCRX common stock for $13.44 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 438 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 405 shares. PCRX also paid $23.04 to the reporting person in lieu of a fractional share.
On March 7, 2013, the reporting person exercised a warrant to purchase 20,069 shares of PCRX common stock for $13.44 per share. The reporting person paid the exercise price on a cashless basis, resulting in PCRX's withholding of 10,407 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 9,662 shares. PCRX also paid $22.08 to the reporting person in lieu of a fractional share.
The securities are held directly by Fred Middleton. The address for Fred Middleton is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
The prior Form 4 did not include Mr. Middleton as a reporting person. This amended Form 4 has been filed solely to add Mr. Middleton as a reporting person.